Today it was reported that the EVP, Chief Business Officer of Acceleron Pharma (XLRN – Research Report), John Quisel, exercised options to buy 8,908 XLRN shares at $4.81 a share, for a total transaction value of $42.91K.
Following this transaction John Quisel’s holding in the company was increased by 17.84% to a total of $2.6 million. Following John Quisel’s last XLRN Buy transaction on August 03, 2015, the stock climbed by 12.6%.
Currently, Acceleron Pharma has an average volume of 252.9K.
Based on 7 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $63.57, reflecting a 56.7% upside. Five different firms, including Citigroup and Cowen & Co., currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $486.3K worth of XLRN shares and purchased $233.2K worth of XLRN shares. The insider sentiment on Acceleron Pharma has been neutral according to 32 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.